Loading clinical trials...
Loading clinical trials...
Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Research has shown that acute ingestion of Paraxanthine (1,7-dimethylxanthine, PXN) can enhance various markers of focus, including memory, reaction time, and attention in healthy adults. To assess these effects, this placebo-controlled crossover trial will compare the effects of 200 and 300mg of PXN to a placebo control. Participants will abstain from caffeine for 3 days, before taking the first test/placebo product for 3 consecutive days. Participants will complete questionnaires at 30, 60, 90, and 120 minutes after ingestion on Day 1 and Day 3 of ingestion. Participants will have a 3-day washout period before trialing the next test product/placebo.
Following enrollment to the study, participants will abstain from any products containing caffeine, for 3 days. On the night of the 3rd day of caffeine abstinence, participants will fast overnight (\~10 hours) The morning after the fast, participants will complete the Day 1 baseline questionnaire. Participants will then consume Test Product A and complete questionnaires 30, 60, 90, and 120 minutes after ingestion. Test Products should be consumed in a fasted state, and 1-hour post-ingestion participants will consume a standardized meal (See Section 6.3). On Day 2, participants will consume Test Product A again but will not complete any questionnaires. The product should be consumed in a fasted state and participants will consume the standardized meal 60 minutes post-ingestion. On Day 3, participants will consume Test Product A in a fasted state and will again consume the standardized meal 1-hour following ingestion of the product. Participants will complete questionnaires 30, 60, 90, and 120 minutes after ingestion. Participants will then have a 3-day washout period with no products consumed or questionnaires completed. Following the washout period, the intervention cycle will be repeated with Test Product B and, subsequently, Test Product C. The questionnaires will consist of study-specific surveys and a cognitive assessment battery.
Age
18 - 35 years
Sex
ALL
Healthy Volunteers
Yes
Citruslabs
Santa Monica, California, United States
Start Date
July 18, 2023
Primary Completion Date
October 18, 2023
Completion Date
October 20, 2023
Last Updated
November 7, 2023
45
ACTUAL participants
Paraxanthine 200 mg
OTHER
Paraxanthine 300 mg
OTHER
Placebo
OTHER
Lead Sponsor
Iovate Health Sciences International Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06962605